Table 3- observational studies Study Methods Type of Bacteria (MIC Outcome Effect on Effect summary carbapenem in mg/L) defined 1 outcome Falagas Clinical, Meropenem Colistin alone In-hospital death 0/14 vs. _ 2006 [] retrospective (14 patients) (colistin vs. combi) More deaths with 21⁄57 (most pneumonia, mostly Response (36.8%), combi P. 24% bacteremia) p=0.007 aeruginosa Combi (57 12/14 patients (mostly Nephrotoxicity (85.7%) vs. A. baumannii) 39⁄57 (68.4%), NS 0/14 vs. 4⁄57 (7%), NS Qureshi Clinical, NS (probably CR Death (colistin vs. 4/7 (57.1%) + K. 2012 [] retrospective (all mostly combi) vs. 1/5 Less deaths with Pneumoniae bacteremia) imipenem) MIC50 colistin (20%) combi MIC ≤0.25,
Table 3- observational studies Study Methods Type of carbapenem 1 Bacteria (MIC in mg/L) Outcome Effect on defined outcome Effect summary Falagas 2006 [] Clinical, retrospective (most pneumonia, 24% bacteremia) Meropenem Colistin alone (14 patients) mostly P. aeruginosa Combi (57 patients (mostly A. baumannii) In-hospital death (colistin vs. combi) Response Nephrotoxicity 0/14 vs. 21⁄57 (36.8%), p=0.007 12/14 (85.7%) vs. 39⁄57 (68.4%), NS 0/14 vs. 4⁄57 (7%), NS _ More deaths with combi Qureshi 2012 [] Clinical, retrospective (all bacteremia) NS (probably mostly imipenem) CR K. Pneumoniae MIC50 colistin MIC ≤0.25, Death (colistin vs. combi) 4/7 (57.1%) vs. 1/5 (20%) + Less deaths with combi